Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 4, 2014, Pages

  Broccoli, Alessandro ^a   Pellegrini, Cinzia ^a   Celli, Monica ^a   Argnani, Lisa ^a   Agostinelli, Claudio ^a   Pileri, Stefano ^a   Zinzani, Pier Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Angioimmunoblastic T cell lymphoma; Complete response; Lenalidomide; Splenomegaly; Vascular endothelial growth factor

Indexed keywords

LENALIDOMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ADULT; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; LABORATORY TEST; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; ANALOGS AND DERIVATIVES; AUTOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOBLASTIC LYMPHADENOPATHY; LYMPH NODE; LYMPHOMA, T-CELL; METASTASIS; PATHOLOGY; RECURRENT DISEASE; RETREATMENT; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOBLASTIC LYMPHADENOPATHY; LYMPH NODES; LYMPHOMA, T-CELL; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDNISONE; RECURRENCE; RETREATMENT; THALIDOMIDE; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84904556753     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.01.011     Document Type: Article

References (16)

1. M. Federico, T. Rudiger, and M. Bellei et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the International Peripheral T-cell Lymphoma Project J Clin Oncol 31 2013 240 246
2. P.P. Piccaluga, C. Agostinelli, and A. Califano et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation Cancer Res 67 2007 10703 10710
3. W.L. Zhao, S. Mourah, and N. Mounier et al. Vascular endothelial growth factor-A is expressed on both lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression Lab Invest 84 2004 1512 1519
4. K. Dunleavy, W.H. Wilson, and E. Jaffe Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications Cur Opin Hematol 14 2007 348 353
5. F. D'Amore, T. Relander, and G.F. Lauritzsen et al. Upfront autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01 J Clin Oncol 30 2012 3093 3099
6. C. Kyriakou, C. Canals, and A. Goldstone et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of outcome - Lymphoma Working Party of the European Group for Blood and Marrow Transplantation J Clin Oncol 26 2008 218 224
7. J. Schetelig, S. Fetscher, and A. Reichle et al. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation Haematologica 88 2003 1272 1278
8. A. Dodero, F. Spina, and F. Narni et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect Leukemia 26 2012 520 526
9. S. Le Gouill, N. Milpied, and A. Buzyn et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire J Clin Oncol 26 2008 2264 2271
10. M. Desai, K.J. Newberry, and J. Romaguera et al. Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B-cell lymphoma: current data on safety and efficacy J Hematol Oncol 6 2013 55
11. G.S. Dueck, N. Chua, and A. Prasad et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma Cancer 116 2010 4541 4548
12. P.L. Zinzani, C. Pellegrini, and A. Broccoli et al. Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified Leuk Lymphoma 52 2011 1585 1588
13. F. Morschhauser, O. Fitoussi, and C. Haioun et al. A phase 2, multicentre, single-arm, open label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in patients with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial Eur J Cancer 49 2013 2869 2876
14. M.M. Beckers, and G. Huls Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide Eur J Haematol 90 2013 162 163
15. A. Fabbri, E. Cencini, and A. Pietrini et al. Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up Hematol Oncol 31 2013 213 217
16. K. Ramasamy, Z. Lim, and A. Pagliuca et al. Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone Haematologica 91 suppl 8 2006 117 118